ARCHIVES

Cobimetinib-Zelboraf Therapy Increases OS In BRAF V600 Mutation-Positive Disease

This article is from The Cancer Letter archive.

Vol. 37 No. 10 | October 31, 2014

Download PDF Visit The Full Archive

Related Articles

“Bring Contracts Under Control, Save $100,00 A Year,” Samuels Tells NCI

November 2, 1979

NCI Won’t Recognize Wolmark Wile NSABP is Plaintiff In Suit

November 18, 1994

Court Upholds FDA Position On Definition Of A Drug.

February 23, 2001

In Brief: John Campbell, Nida Contracts Chief, New Head Of NCI Contracts Branch; PHS Honors Seven At NCI

June 10, 1983

Study tests a “truth” in radiation oncology, raises questions about anemia treatment.

October 24, 2003

Tobacco Regulation: ACS Advocates Giving FDA Full Authority Over Tobacco

January 23, 1998